Arcus Biosciences
RCUS
78 hedge funds and large institutions have $210M invested in Arcus Biosciences in 2019 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 3 closing their positions.
533% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 3
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
22% more funds holding
Funds holding: 64 → 78 (+14)
1.37% more ownership
Funds ownership: 57.99% → 59.37% (+1.4%)
35% less capital invested
Capital invested by funds: $323M → $210M (-$113M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$7.26M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$4.99M |
| 3 |
BlackRock
New York
|
+$4.05M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$1.34M |
| 5 |
Morgan Stanley
New York
|
+$888K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$16.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$696K |
| 3 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$313K |
| 4 |
AG
Artal Group
Luxembourg
|
-$300K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$204K |
RCUS Hedge Fund Activity: Q2 2019 in Review
78 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2019, worth a combined $210M — down 35% from $323M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RCUS positions and 3 closed out — a net gain of 16 holders — while 27 added to existing stakes and 13 trimmed.
The largest buyer was BVF Inc, adding an estimated $7.26M. The largest seller was Wellington Management Group, cutting an estimated $16.1M.
- 78 institutional investors held Arcus Biosciences (RCUS) as of Q2 2019, up from 64 in Q1 2019.
- Funds reported $210M of Arcus Biosciences stock for Q2 2019, down 35% quarter-over-quarter.
- 19 funds opened new Arcus Biosciences positions in Q2 2019 and 3 closed out, a net change of +16 holders.
- The largest Arcus Biosciences buyer in Q2 2019 was BVF Inc, an estimated $7.26M added.
- The largest Arcus Biosciences seller in Q2 2019 was Wellington Management Group, an estimated $16.1M sold.
Based on aggregated 13F filings for Q2 2019.